Ciclesonide: Uses, Dosage, and Side Effects

Ciclesonide is an inhaled corticosteroid prescribed for two conditions: persistent asthma and allergic rhinitis. What sets it apart from older inhaled steroids is its design as a prodrug, meaning the medication you inhale is inactive until enzymes in your lungs switch it on. That feature shapes nearly everything about how ciclesonide works, what side effects it causes, and why some doctors prefer it for certain patients.

How Ciclesonide Activates in the Lungs

When you inhale ciclesonide, the molecule that lands in your airways is pharmacologically inert. Enzymes called esterases in the lung tissue then cleave off part of the molecule to produce its active form, called desisobutyryl-ciclesonide, or des-CIC for short.¹ This local activation matters because any ciclesonide that accidentally ends up in your mouth or throat stays inactive there, and any that gets swallowed and absorbed from the gut remains largely inactive in the bloodstream. The result is a drug that concentrates its anti-inflammatory punch right where you need it.

Once des-CIC forms in the lungs, it can also attach to fatty acids in lung tissue through a process called lipid conjugation. This acts like a slow-release reservoir, extending how long the drug stays active in the airways.² Meanwhile, any des-CIC that does reach the bloodstream is about 99% bound to plasma proteins, leaving very little free drug circulating to trigger unwanted effects elsewhere in the body.³ Combine that with rapid clearance from the blood, low oral bioavailability, and the local-activation design, and you get a corticosteroid built to minimize systemic exposure.⁴

Approved Uses

Asthma

Ciclesonide is approved as a maintenance treatment for persistent asthma in adults, adolescents, and in some countries, children. It is not a rescue inhaler and does not work quickly enough to stop an asthma attack in progress. Instead, you use it daily to keep airway inflammation in check. In multiple 12-week trials that included both adults and children with varying severity of asthma, ciclesonide improved lung function, reduced asthma symptoms, and cut the need for rescue medication compared to placebo.⁵ It also performed at least as well as budesonide and fluticasone propionate in maintaining lung function and asthma control.⁶

One practical advantage is dosing frequency. Once-daily ciclesonide has shown results comparable to twice-daily budesonide or fluticasone.⁵ For people who struggle to remember a midday or evening dose, that can make a real difference in how consistently the medication gets used.

Allergic Rhinitis

Ciclesonide is also available as a nasal spray for allergic rhinitis, both seasonal and year-round. A systematic review and meta-analysis of trials in perennial allergic rhinitis found that ciclesonide significantly reduced total nasal symptom scores and improved quality of life compared to placebo, without increasing the rate of adverse events.⁷

Reaching the Small Airways

Most of the inflammation in asthma happens throughout the bronchial tree, including the smaller airways that many older inhaled corticosteroids do not reach very well. Ciclesonide is formulated as a solution-based metered-dose inhaler that produces very small particles, and those particles travel deeper into the lungs than larger ones typically do.² A study measuring markers of small-airway inflammation found that ciclesonide reduced both alveolar exhaled nitric oxide (a marker of deep-lung inflammation) and air trapping visible on CT scans, indicating that the drug’s anti-inflammatory effects genuinely extend into the small airways.⁸ For patients whose asthma is driven heavily by small-airway disease, this can be clinically meaningful.

Typical Dosage

Ciclesonide for asthma is delivered through a hydrofluoroalkane metered-dose inhaler, usually at doses between 80 and 320 micrograms per day for adults, depending on asthma severity. Most adults start at 80 or 160 micrograms once daily. For children studied in clinical trials, doses of 40, 80, and 160 micrograms once daily all improved lung function compared to placebo, and all three doses were well tolerated.⁹ The nasal spray for allergic rhinitis is typically dosed at 200 micrograms per day, sprayed as one or two sprays per nostril. Your prescriber adjusts the dose based on how well your symptoms respond and how severe they were to begin with.

Local Side Effects

The two most common local side effects of any inhaled corticosteroid are oral thrush (candidiasis) and hoarseness (dysphonia). Both happen because active steroid particles deposit in the mouth and throat, suppressing local immune defenses and irritating vocal cord tissue. Because ciclesonide arrives inactive and only turns on inside the lungs, less active drug sits in the oropharynx. A Cochrane review comparing ciclesonide to other inhaled steroids for chronic asthma found lower rates of oral candidiasis with ciclesonide than with fluticasone.¹⁰ Separate research has also pointed to less oropharyngeal deposition with ciclesonide and correspondingly lower rates of both candidiasis and dysphonia compared to other inhaled steroids.¹¹

If you have switched to ciclesonide specifically because oral thrush was a recurring problem with a previous inhaler, the prodrug design is the main reason your doctor considered it. Rinsing and spitting after using any inhaled corticosteroid remains good practice, but the advantage with ciclesonide is that there is less active drug in the mouth to begin with.

Systemic Side Effects and the Cortisol Question

A major concern with any corticosteroid, inhaled or not, is whether the drug suppresses your body’s own cortisol production. Cortisol is a hormone your adrenal glands make to regulate metabolism, immune function, and stress response. When an inhaled steroid leaks into the bloodstream in large enough amounts, it can signal the adrenal glands to dial back their output, a phenomenon called hypothalamic-pituitary-adrenal (HPA) axis suppression.

Ciclesonide performs well on this front. A head-to-head trial comparing ciclesonide (at 320 and 640 micrograms per day) against fluticasone propionate (at 500 and 1,000 micrograms per day) found that fluticasone significantly suppressed cortisol secretion at both doses, while neither dose of ciclesonide had a statistically significant suppressive effect.¹² A broader systematic review of inhaled corticosteroids and adrenal suppression confirmed that ciclesonide was not associated with significant urinary cortisol suppression, attributing this to its pharmacokinetic design rather than simply a novel formulation.¹³

Use in Children

Parents and pediatricians worry about two things with long-term inhaled steroids in children: growth suppression and adrenal effects. The evidence on ciclesonide is more reassuring than for some alternatives.

In a trial of children aged 5 to 8 with mild persistent asthma, ciclesonide at doses up to 160 micrograms per day showed no detectable effect on growth velocity compared to placebo, even at the highest dose tested. Overnight and 24-hour urinary cortisol levels were also unchanged.¹⁴ A separate study using sensitive lower-leg growth measurements in children aged 6 to 12 reinforced this finding. Ciclesonide showed no statistically significant difference in lower-leg growth rate compared to placebo, while a similar dose of fluticasone propionate significantly reduced growth rate compared to both placebo and ciclesonide.¹⁵

For efficacy, all tested doses of ciclesonide (40, 80, and 160 micrograms daily) improved peak expiratory flow, symptoms, and quality of life in children with persistent asthma. Adverse event rates were comparable to placebo, and using a spacer device did not change either the efficacy or the safety profile.⁹ Improvements in lung function were also confirmed in a separate 12-week trial across multiple ciclesonide doses, with no effect on HPA axis function.¹⁶

How Ciclesonide Compares to Other Inhaled Steroids

The practical question for most people is whether ciclesonide works better, worse, or about the same as the inhaled steroids already on the market. The short answer is that asthma control is broadly similar, but the side effect profile differs.

A Cochrane review of ciclesonide versus budesonide and fluticasone in children found no meaningful differences in asthma symptoms or exacerbation rates at equivalent or 1:2 dose ratios.¹⁷ When ciclesonide was compared to budesonide at a 1:2 dose ratio, urine cortisol levels were significantly lower (less suppressed) in the ciclesonide group, suggesting a systemic safety advantage. Against fluticasone at a 1:1 ratio, cortisol levels were similar between the two drugs. One finding worth noting: in a single study comparing ciclesonide to double-dose fluticasone, children on ciclesonide had more exacerbations, which makes sense because they were receiving half the steroid potency.¹⁷

In adults, a 24-week trial comparing low-dose ciclesonide to fluticasone propionate in mild to moderate asthma showed that both drugs significantly improved lung function from baseline. Ciclesonide was formally non-inferior to fluticasone, and exacerbation rates, asthma control days, and quality-of-life scores were comparable between the two.¹⁸ Where ciclesonide consistently stands out is on local and systemic safety markers rather than raw efficacy.

Ocular Safety

Long-term corticosteroid use, whether systemic or inhaled, has historically raised concerns about eye problems like cataracts and glaucoma. A year-long trial specifically designed to assess lens opacity found that ciclesonide at 640 micrograms per day produced changes in lens measurements that were small and virtually identical to those seen with beclomethasone dipropionate at the same dose. Ciclesonide was formally non-inferior to beclomethasone on the primary eye outcome.¹⁹ More broadly, a review of intranasal corticosteroid safety concluded that this class of drugs does not increase the risk of cataracts or glaucoma, though scattered case reports of transient increases in intraocular pressure exist.²⁰

Drug Interactions Worth Knowing About

Once des-CIC reaches the liver, it is broken down mainly by the CYP3A4 enzyme.²¹ That matters because a number of common medications block CYP3A4, and if the enzyme is inhibited, des-CIC sticks around longer in the body. A study using ketoconazole, a strong CYP3A4 inhibitor, found that ketoconazole roughly tripled the blood levels of des-CIC. The activation step from ciclesonide to des-CIC was unaffected, but the elimination of des-CIC slowed substantially.²²

In practice, because ciclesonide produces such low systemic levels to begin with, this interaction is less clinically worrisome than it would be with an inhaled steroid that already has high systemic exposure. Still, if you are taking a strong CYP3A4 inhibitor (ketoconazole, itraconazole, ritonavir, or clarithromycin are common examples), your doctor should be aware so they can monitor for any signs of increased corticosteroid effect.

Antiviral Research During the Pandemic

Ciclesonide attracted attention early in the COVID-19 pandemic when laboratory studies found that it could suppress the replication of SARS-CoV-2 in cultured cells. The active metabolite appeared to interfere with the viral replication-transcription complex, and in one study, the concentration needed to block 90% of viral replication in differentiated human airway cells was relatively low.²³ Researchers even generated ciclesonide-resistant SARS-CoV-2 mutants in the lab, but the drug still suppressed replication of those mutants by 90% or more, suggesting the virus could not easily escape the blockade.

Follow-up work explored chemical modifications of ciclesonide to boost the antiviral effect. Some derivatives showed stronger viral copy-number reduction than the parent compound, positioning them as possible leads for antiviral drug development.²⁴ These findings were intriguing, but the path from cell-culture activity to proven clinical benefit is long. Large clinical trials of inhaled ciclesonide for COVID-19 produced mixed results, and it has not become a standard treatment for the disease. The research remains scientifically interesting as an example of an established drug showing unexpected antiviral properties, but the practical takeaway for patients using ciclesonide for asthma is that this was an exploratory detour, not a change in how the drug is used.

Cost and Accessibility

One barrier to wider ciclesonide use is price. A cost-utility analysis comparing ciclesonide to budesonide for mild to moderate asthma maintenance found that ciclesonide’s incremental cost per quality-adjusted life year gained was far above typical willingness-to-pay thresholds, making it less economical at current pricing. The analysis suggested ciclesonide would need a substantial price reduction to achieve cost parity with budesonide.²⁵ That analysis came from one country’s pricing structure and may not translate directly everywhere, but the general pattern holds in many markets: budesonide and fluticasone are available as generics, while ciclesonide is often still brand-name and priced accordingly.

For someone whose asthma is well controlled on a generic inhaled steroid without troublesome side effects, the extra cost of ciclesonide may not be justified. Where the math changes is for patients who develop oral thrush repeatedly, experience hoarseness that interferes with their daily life, or are children whose parents and physicians want to minimize any risk of growth suppression. In those situations, the safety profile advantages that ciclesonide offers can justify the premium, and insurers sometimes cover it when a prior authorization documents why another inhaled steroid was inadequate.

1
European Respiratory Journal. Deposition and metabolism of inhaled ciclesonide in the human lung
2
PubMed. Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide
3
PubMed. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide
4
PubMed. Ciclesonide: A Pro-Soft Drug Approach for Mitigation of Side Effects of Inhaled Corticosteroids
5
PubMed Central. Ciclesonide for the treatment of asthma
6
PubMed Central. Profile of ciclesonide for the maintenance treatment of asthma
7
PubMed Central. The efficacy and safety of ciclesonide for the treatment of perennial allergic rhinitis: a systematic review and meta-analysis
8
PubMed. Ciclesonide improves measures of small airway involvement in asthma
9
PubMed. Efficacy and safety of three ciclesonide doses vs placebo in children with asthma: the RAINBOW study
10
Cochrane Database of Systematic Reviews. Ciclesonide versus other inhaled steroids for chronic asthma in children and adults
11
PubMed. Dysphonia associated with the use of inhaled corticosteroids
12
European Respiratory Journal. Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma
13
PubMed. Adrenal suppression by inhaled corticosteroids in patients with asthma: A systematic review and quantitative analysis
14
Pediatrics. Assessment of the Long-term Safety of Inhaled Ciclesonide on Growth in Children With Asthma
15
PubMed. Lower-leg growth rates in children with asthma during treatment with ciclesonide and fluticasone propionate
16
PubMed. Once-daily ciclesonide in children: efficacy and safety in asthma
17
PubMed Central. Ciclesonide versus other inhaled corticosteroids for chronic asthma in children
18
PubMed. A 24-week comparison of low-dose ciclesonide and fluticasone propionate in mild to moderate asthma
19
PubMed. A randomized, controlled trial to investigate the effect of ciclesonide and beclomethasone dipropionate on eye lens opacity
20
PubMed. Safety of intranasal corticosteroids
21
PubMed. Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes
22
PubMed. Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl-ciclesonide
23
PubMed Central. The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells
24
PubMed Central. Antiviral activity of ciclesonide acetal derivatives blocking SARS-CoV-2 RNA replication
25
ZHONGGUO YAOFANG. Cost-utility analysis of ciclesonide and budesonide in the treatment of mild to moderate bronchial asthma